公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

Applicant: AbbVie Inc.

Inventor： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC: C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240355416A1

公开(公告)日：2024-10-24

申请号：US18753994

申请日：2024-06-25

Applicant: Scipher Medicine Corporation

Inventor： Susan GHIASSIAN ,  Theodore R. MELLORS ,  Marc SANTOLINI ,  Asher AMELI ,  Nancy SCHOENBRUNNER ,  Viatcheslav R. AKMAEV ,  Keith J. JOHNSON

IPC: G16B20/20 ,  A61K38/17 ,  A61P19/02 ,  A61P37/06 ,  C07K16/24 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70

CPC classification number: G16B20/20 ,  A61K38/1793 ,  A61P19/02 ,  A61P37/06 ,  C07K16/241 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76

Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.

公开(公告)号：US12122814B2

公开(公告)日：2024-10-22

申请号：US18501584

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US12116392B2

公开(公告)日：2024-10-15

申请号：US18501884

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US20240336699A1

公开(公告)日：2024-10-10

申请号：US18750233

申请日：2024-06-21

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Sonny Oon ANG ,  Enli LIU ,  Elizabeth SHPALL ,  Katy REZVANI

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P37/06 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N15/52 ,  C12N15/86

CPC classification number: C07K16/2896 ,  A61K35/17 ,  A61P37/06 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2863 ,  C12N15/52 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

公开(公告)号：US20240336665A1

公开(公告)日：2024-10-10

申请号：US18708113

申请日：2022-11-07

Applicant: Acroimmune Guangzhou Biotech Ltd

Inventor： Qunmin ZHOU ,  Xianfeng FANG ,  Dongling LI ,  Libing MU

IPC: C07K14/47 ,  A61K38/00 ,  A61P37/06

CPC classification number: C07K14/4727 ,  A61P37/06 ,  A61K38/00 ,  C07K2319/30

Abstract: Provided are compositions of proteins based on fusion of one or more copy of the core peptide to the Fc fragment of human immunoglobulin and their use in treating diseases propagated by inflammations associated with tissue injuries.

公开(公告)号：US20240335545A1

公开(公告)日：2024-10-10

申请号：US18627930

申请日：2024-04-05

Applicant: The Medical College of Wisconsin, Inc.

Inventor： William R. Clarke ,  Brian F. Volkman ,  Francis C. Peterson ,  Michael B. Dwinell ,  Chad A. Koplinski

IPC: A61K47/55 ,  A61K38/19 ,  A61P37/06

CPC classification number: A61K47/55 ,  A61K38/195 ,  A61P37/06

Abstract: Disclosed are methods of treating graft versus host disease (GVHD) or treating ocular graft versus host disease (oGVHD). The methods may comprise administering a therapeutically effective amount of a composition comprising CCL20 locked dimer to a subject, e.g., a subject suffering from GVHD. Also disclosed are modified CCL20LD compositions comprising an unstructured polypeptide.

公开(公告)号：US20240335484A1

公开(公告)日：2024-10-10

申请号：US18294358

申请日：2022-08-18

Applicant: SOCIETE DES PRODUITS NESTLE S.A.

Inventor： KATJA JOHNSON

IPC: A61K35/745 ,  A61P37/06

CPC classification number: A61K35/745 ,  A61P37/06

Abstract: The present invention provides a Bifidobacterium lactis supernatant for use in enhancing expression of anti-inflammatory cytokines and/or reducing expression of pro-inflammatory chemokines in the gastrointestinal tract of a subject having or at risk of an overactive immune system disorder. The present invention also provides a Bifidobacterium lactis supernatant for use in enhancing expression of IL-10 in the gastrointestinal tract of a subject having or at risk of an IL-10 mediated disease. The present invention also provides a Bifidobacterium lactis supernatant for use in treating or preventing an IL-10 mediated disease by enhancing expression of IL-10 in the gastrointestinal tract of a subject.

公开(公告)号：US20240327489A1

公开(公告)日：2024-10-03

申请号：US18580770

申请日：2022-07-20

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Casandra M. Panea ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan ,  Julie Horowitz

IPC: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/28 ,  G01N33/50

CPC classification number: C07K14/70503 ,  A61P29/00 ,  A61P37/06 ,  C07K16/2803 ,  G01N33/505 ,  A61K38/00 ,  A61K2039/505 ,  C07K2319/33

Abstract: This disclosure provides methods for treating T cell-driven inflammatory disorders. The methods include administering to a subject a therapeutically effective amount of a butyrophilin-like 2 (Btnl2) agent capable of increasing a level or activity of Btnl2, thereby altering the frequencies or function of lymphocytes in the subject.

公开(公告)号：US20240325468A1

公开(公告)日：2024-10-03

申请号：US18575198

申请日：2022-07-06

Applicant: LISCURE BIOSCIENCES INC.

Inventor： Hwa Sup CHIN

IPC: A61K35/747 ,  A61P37/06 ,  C12N1/20 ,  C12R1/225

CPC classification number: A61K35/747 ,  A61P37/06 ,  C12N1/205 ,  C12R2001/225

Abstract: The present disclosure relates to a composition containing Lactobacillus sakei or extracellular vesicles derived therefrom. The present disclosure also relates to a novel Lactobacillus sakei LBML6 strain. The Lactobacillus sakei according to the present disclosure is a strain which has inhibitory activity against TNFα and IgG in blood and in which the proportion of tolDC cells and Treg cells is increased, and can be used for various applications such as the prevention, alleviation and/or treatment of autoimmune disease in human or animals as well as intestinal regulation.